Comparable stake leader
FMR LLC
SEC ownership of Avalyn Pharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001540171.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- AVLN on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001540171
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Avalyn Pharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
13%
Novo Holdings A/S
8.8%
Norwest Venture Partners XV, LP
5.1%
SR ONE CAPITAL MANAGEMENT, LP
7.5%
PERCEPTIVE ADVISORS LLC
6.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
3/4/5
Company · Other*, 10%+ Owner
|
13%
from 13D/G
|
$192,096,726
5,835,259 shares
|
— | 30 Jun 2026 |
| Novo Holdings A/S |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
8.8%
from 13D/G
|
$127,837,874
3,883,289 shares
|
— | 30 Jun 2026 |
| Norwest Venture Partners XV, LP |
13D/G
|
5.1%
|
$63,152,367
2,268,404 shares
|
$0 | 30 Jun 2026 |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
Company
|
7.5%
|
$108,920,725
3,308,649 shares
|
— | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
6.1%
|
$88,070,744
2,675,296 shares
|
— | 30 Jun 2026 |
| MONTANOVA CAPITAL, LLC |
13F
Company
|
5.7%
|
$82,402,348
2,503,109 shares
|
— | 30 Jun 2026 |
| NVP Associates, LLC |
13F
Company
|
5.1%
|
$74,675,860
2,268,404 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
Company
|
5%
|
$72,489,379
2,201,986 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 05 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Avalyn Pharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
David Matthew Friedman
Net 12M change
$0
Latest report
01 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David Matthew Friedman | Director | Mixed | 29 Apr 2026 | |||
| Lyn Baranowski | Chief Executive Officer, Director | Mixed | 29 Apr 2026 | |||
| Howard Lazarus | Chief Medical Officer | Mixed | 29 Apr 2026 | |||
| Kate Haviland | Director | Mixed | 29 Apr 2026 | |||
| Douglas R. Carlson | Chief Financial Officer | Mixed | 29 Apr 2026 | |||
| Melissa Rhodes | Chief Operating Officer | Mixed | 29 Apr 2026 | |||
| Heather D. Turner | Director | Mixed | 29 Apr 2026 | |||
| Jon Congleton | Director | Mixed | 29 Apr 2026 | |||
| Adam H. Golden | General Counsel | Mixed | 29 Apr 2026 | |||
| Erin Lavelle | Director | Mixed | 29 Apr 2026 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | 10%+ Owner | Mixed | 01 May 2026 | |||
| Simeon George | 10%+ Owner | Mixed | 01 May 2026 | |||
| Jill Carroll | Director | Mixed | 01 May 2026 | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | Mixed | 01 May 2026 | |||
| FMR LLC | Other*, 10%+ Owner | Mixed | 01 May 2026 | |||
| Novo Holdings A/S | 10%+ Owner | Mixed | 01 May 2026 |
Recent insider transactions for Avalyn Pharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | AVLN | Voting Common Stock | Purchase | 16.7% | 555,555 | 3,883,289 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Voting Common Stock | Conversion of derivative security | 3,327,734 | 3,327,734 | 01 May 2026 | Direct | |||
| Novo Holdings A/S | AVLN | Series D Preferred Stock | Conversion of derivative security | -100% | -12,558,081 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series C-2 Preferred Stock | Conversion of derivative security | -100% | -5,587,603 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series C-1 Preferred Stock | Conversion of derivative security | -100% | -25,899,284 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series B Preferred Stock | Conversion of derivative security | -100% | -1,986,369 | 0 | 01 May 2026 | Direct | ||
| Novo Holdings A/S | AVLN | Series A Preferred Stock | Conversion of derivative security | -100% | -18,000,000 | 0 | 01 May 2026 | Direct | ||
| Fmr Llc | AVLN | Common Stock | Conversion of derivative security | 2,284,535 | 2,284,535 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | |||
| Fmr Llc | AVLN | Series D Preferred Stock | Conversion of derivative security | -100% | -377,948 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series C-2 Preferred Stock | Conversion of derivative security | -100% | -225,843 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series C-1 Preferred Stock | Conversion of derivative security | -100% | -872,868 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series B Preferred Stock | Conversion of derivative security | -100% | -80,291 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Fmr Llc | AVLN | Series A Preferred Stock | Conversion of derivative security | -100% | -727,585 | 0 | 01 May 2026 | F-Prime Capital Partners Healthcare Fund V LP | ||
| Jill Carroll | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| Jill Carroll | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| Jill Carroll | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| Jill Carroll | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Purchase | 32.9% | 277,777 | 1,122,087 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Common Stock | Purchase | 32.9% | 277,777 | 1,122,087 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Conversion of derivative security | 844,310 | 844,310 | 01 May 2026 | See Note 4 | |||
| Sr One Capital Management, Llc | AVLN | Common Stock | Conversion of derivative security | 844,310 | 844,310 | 01 May 2026 | See Note 4 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Common Stock | Purchase | 14.6% | 277,778 | 2,186,562 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| Sr One Capital Management, Llc | AVLN | Common Stock | Conversion of derivative security | 1,908,784 | 1,908,784 | 01 May 2026 | See Note 2 | |||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,560 | 0 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,560 | 0 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -6,827,429 | 0 | 01 May 2026 | See Note 4 | ||
| Sr One Capital Management, Llc | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -6,827,429 | 0 | 01 May 2026 | See Note 4 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -9,418,561 | 0 | 01 May 2026 | See Note 2 | ||
| SR ONE CAPITAL MANAGEMENT, LLC | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| Sr One Capital Management, Llc | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -27,309,719 | 0 | 01 May 2026 | See Note 2 | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Common Stock | Conversion of derivative security | 1,275,486 | 1,275,486 | 01 May 2026 | Direct | |||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Series D Convertible Preferred Stock | Conversion of derivative security | -100% | -4,060,259 | 0 | 01 May 2026 | Direct | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | AVLN | Series C-1 Convertible Preferred Stock | Conversion of derivative security | -100% | -20,482,289 | 0 | 01 May 2026 | Direct | ||
| Douglas R. Carlson | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 30 Apr 2026 | Direct | |||
| Erin Lavelle | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 30 Apr 2026 | Direct | |||
| Adam H. Golden | AVLN | Stock Option (Right to Buy) | Award | 254,891 | 254,891 | 29 Apr 2026 | Direct | |||
| Jon Congleton | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Heather D. Turner | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Melissa Rhodes | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 29 Apr 2026 | Direct | |||
| Kate Haviland | AVLN | Stock Option (Right to Buy) | Award | 26,978 | 26,978 | 29 Apr 2026 | Direct | |||
| Howard Lazarus | AVLN | Stock Option (Right to Buy) | Award | 211,975 | 211,975 | 29 Apr 2026 | Direct | |||
| Lyn Baranowski | AVLN | Stock Option (Right to Buy) | Award | 501,033 | 501,033 | 29 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.